Mind Medicine (MNMD) has released an update.
Mind Medicine, a biopharmaceutical company focused on brain health disorders, will present its research on the impact of COVID-19 on Generalized Anxiety Disorder at two key medical conferences in April 2024. The presentations will highlight findings related to the prevalence and demographics of the disorder in Europe and the U.S. Post-conference, the research posters will be accessible on the company’s website.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
